Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04419831 · ClinicalTrials.gov registry record
Characterizing Subjective and Physiological Responses to Stress and Pain and Cognitive Learning and Executive Function
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 81
- Enrollment target
NCT04419831: Completed study, sponsored by Yale University.
NCT04419831 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04419831 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 81 participants
- Enrollment target
Study Summary
The study design is to assess the between groups factor (controls, chronic pain, addicted individuals) and repeated measures factor of pain/stress (pain vs no pain) along with a longitudinal component to assess stress, pain and addictive behaviors in daily life.
Primary Outcome
Pain will be assessed by asking participants, "Right now, how much pain do you feel?" asked using the VAS scale ranging from 0 to 100 as outlined in the Laboratory Pain Ratings assessment
Interventions
- DIAGNOSTIC_TEST Yale Stress Pain Test (YSPT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2023-12-30 |
What the finished NCT04419831 record still lists
NCT04419831 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 81 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Yale Stress Pain Test (YSPT) is the first listed.
NCT04419831 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04419831 about?
NCT04419831 is a clinical study titled "Characterizing Subjective and Physiological Responses to Stress and Pain and Cognitive Learning and Executive Function". The study design is to assess the between groups factor (controls, chronic pain, addicted individuals) and repeated measures factor of pain/stress (pain vs no pain) along with a longitudinal component to assess stress, pain and addictive behaviors in daily life.
What is the current status of trial NCT04419831?
This trial is currently completed. The enrollment target is 81 participants. The study started on 2022-04-14. Estimated completion is 2023-12-30.
What interventions are being tested in trial NCT04419831?
The interventions under investigation include: Yale Stress Pain Test (YSPT) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04419831?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI